Top

22-04-2017 | Psoriatic arthritis | Review | Article

TNF Inhibitors for Psoriasis and Psoriatic Arthritis

Journal: Current Dermatology Reports

Authors: Leah A. Cardwell, Brandy Sullivan, Emilia Baran, Elias Oussedik, Steven R. Feldman

Abstract

Purpose of Review

A growing body of research highlights the use of TNF inhibitors in the treatment of psoriasis and psoriatic arthritis. We aim to review the literature, compile psoriasis efficacy data for TNF inhibitors, and offer advice regarding the approach to treating this condition.

Recent Findings

The results of randomized placebo-controlled studies indicate that TNF inhibitors are efficacious and well tolerated in the treatment of psoriasis. There is a greater prevalence of anxiety, depression, cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, fatty liver disease, metabolic syndrome, and inflammatory bowel disease in psoriasis patients than in the general population. Severe psoriasis portends an increased risk of mortality.

Summary

Although patients with mild-to-moderate psoriasis do not have an increased mortality rate, the inherent inflammatory nature of psoriasis and its association with serious comorbid conditions may warrant the use of systemic medications, such as TNF inhibitors.

Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol [Internet]. 2010;160(4):810–20. doi:10.1111/j.1476-5381.2010.00702.x.CrossRef

Kirkham B. Tumor necrosis factor-alpha inhibitors: an overview of adverse effects [Internet]. [cited 2016 Dec 31]. Available from: http://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects.

Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol [Internet]. 2008;126(2):121–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17916444.CrossRef

Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess [Internet]. 2006;10(42):iii–v. xi–xiii, 1-229. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17049139.

• Felquer MLA, Soriano ER. New treatment paradigms in psoriatic arthritis. Curr Opin Rheumatol [Internet]. 2015;27(2):99–106. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002281-201503000-00002. This is a review article that consolidates the treatment options for psoriatic arthritis, notably for certolizumab pegol.CrossRef

Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (London, England) [Internet]. 2000;356(9227):385–90. Available from: http://www.sciencedirect.com/science/article/pii/S0140673600025307.CrossRef

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med [Internet]. 2003;349(21):2014–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14627786.CrossRef

Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–72.CrossRefPubMed

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol [Internet]. 2005;152(6):1304–12. doi:10.1111/j.1365-2133.2005.06688.x.CrossRef

10.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med [Internet]. 2008;358(3):241–51. doi:10.1056/NEJMoa066886.CrossRef

11.

Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (London, England) [Internet]. 2001;357(9271):1842–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11410193.CrossRef

12.

Barker J, Hoffmann M, Wozel G, Ortonne J-P, Zheng H, van Hoogstraten H, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol [Internet]. 2011;165(5):1109–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21910713.CrossRef

13.

Reich K, Nestle FO, Papp K, Ortonne J-P, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet [Internet]. 2005;366(9494):1367–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16226614 CrossRef

14.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum [Internet]. 2005;52(10):3279–89. doi:10.1002/art.21306.CrossRef

15.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.CrossRefPubMed

16.

Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671–81.CrossRefPubMed

17.

Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum [Internet]. 2009;60(4):976–86. doi:10.1002/art.24403.CrossRef

18.

•• Kavanaugh A, IB MI, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis [Internet]. 2013;72(11):1777–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23161902. This randomized control trial illustrates the clinical efficacy and safety findings of golimumab in psoriatic arthritis.CrossRef

19.

Reich K, Ortonne J-P, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol [Internet]. 2012;167(1):180–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22413944.CrossRef

20.

•• Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis [Internet]. 2014;73(1):48–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23942868. This randomised trial summarizes the clinical efficacy of certolizumab pegol (200mg vs 400mg) vs placebo.CrossRef

21.

Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol [Internet]. 2014;15(1):37–43. Available from: http://link.springer.com/10.1007/s40257-013-0053-5.CrossRef

22.

• Oliveira Mde FSP, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9. This review article summarizes the most recent comorbities associated with psoriasis.CrossRefPubMed

23.

Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol [Internet]. 2012;132(3):556–62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X15356712.CrossRef

24.

• Tablazon ILD, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients. Am J Clin Dermatol [Internet]. 2013;14(1):1–7. Available from: http://link.springer.com/10.1007/s40257-012-0005-5. This review article summarizes the direct relationship between the risk of cardiovascular disease and the severity of psoriasis.CrossRef

25.

Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol [Internet]. 2014;7:119–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24790463.

26.

• Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol [Internet]. 2012;11(5 Suppl):s5–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22644770. This is a review article complementing reference #22 in summarizing the most recent comorbities associated with psoriasis.

27.

Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis. Arch Dermatol [Internet]. 2007;143(12):1493–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18086997.

Medicine Matters Rheumatology

Abstract

Purpose of Review

Recent Findings

Summary